DK2087904T3 - Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter - Google Patents

Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter

Info

Publication number
DK2087904T3
DK2087904T3 DK09154734.9T DK09154734T DK2087904T3 DK 2087904 T3 DK2087904 T3 DK 2087904T3 DK 09154734 T DK09154734 T DK 09154734T DK 2087904 T3 DK2087904 T3 DK 2087904T3
Authority
DK
Denmark
Prior art keywords
bcl
protein
cancer patients
therapeutic use
peptides derived
Prior art date
Application number
DK09154734.9T
Other languages
English (en)
Inventor
Eivind Per Thor Straten
Mads Hald Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Application granted granted Critical
Publication of DK2087904T3 publication Critical patent/DK2087904T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09154734.9T 2003-11-19 2004-11-18 Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter DK2087904T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
DKPA200301716 2003-11-19
EP04797460A EP1691824B1 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Publications (1)

Publication Number Publication Date
DK2087904T3 true DK2087904T3 (da) 2013-12-02

Family

ID=39149116

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09154734.9T DK2087904T3 (da) 2003-11-19 2004-11-18 Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter
DK04797460T DK1691824T3 (da) 2003-11-19 2004-11-18 Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04797460T DK1691824T3 (da) 2003-11-19 2004-11-18 Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter

Country Status (18)

Country Link
US (1) US7842294B2 (da)
EP (2) EP1691824B1 (da)
JP (2) JP4926714B2 (da)
KR (2) KR101284237B1 (da)
CN (1) CN1921878B (da)
AT (1) ATE424842T1 (da)
AU (1) AU2004290866B2 (da)
CA (1) CA2546794C (da)
DE (1) DE602004019965D1 (da)
DK (2) DK2087904T3 (da)
ES (2) ES2323588T3 (da)
HK (1) HK1101131A1 (da)
MX (1) MXPA06005738A (da)
PL (2) PL2087904T3 (da)
PT (1) PT1691824E (da)
RU (1) RU2367468C2 (da)
WO (1) WO2005049073A2 (da)
ZA (1) ZA200604866B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CN103288920B (zh) * 2003-01-30 2015-08-12 苏瓦克有限公司 存活蛋白衍生肽及其用途
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
WO2006045076A2 (en) * 2004-10-19 2006-04-27 Massachusetts Institute Of Technology Virus scaffold for self-assembled, flexible and light lithium battery
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
AU2006209951B2 (en) * 2005-02-04 2011-04-14 Survac Aps Survivin peptide vaccine
CA2622504A1 (en) * 2005-09-09 2008-03-08 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cel proliferation
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2197908A2 (en) * 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CA2730369A1 (en) * 2008-07-16 2010-01-21 Burnham Institute For Medical Research Compositions and methods for modulating nod-like receptor activity and uses thereof
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
AU2009305617B2 (en) 2008-10-17 2014-01-23 University Of Miami Tumor vaccine
EP3444333A1 (en) * 2009-10-22 2019-02-20 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
BR112012022641A2 (pt) 2010-03-11 2017-02-14 Oncotherapy Science Inc peptídeos hjurp e vacinas que incluem os mesmos
EP2608799B1 (en) * 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP4321218A3 (en) 2012-05-16 2024-04-24 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
EP2877189B1 (en) * 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
EP2961419A4 (en) * 2013-02-26 2016-12-21 Rongfu Wang PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY
EP2961415B1 (en) * 2013-03-01 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
RS64217B1 (sr) * 2017-01-27 2023-06-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jajnika i drugih malignih tumora
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AR110857A1 (es) 2017-01-27 2019-05-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CA3110760A1 (en) 2018-09-04 2020-03-12 Treos Bio Limited Peptide vaccines
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1994005304A1 (en) 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
KR100645448B1 (ko) 1996-11-20 2006-11-13 예일 유니버시티 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
WO1998058541A1 (en) 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
WO2001036594A1 (en) 1999-11-16 2001-05-25 Dartmouth College Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT
EP1238080A2 (en) 1999-12-14 2002-09-11 The Burnham Institute Bcl-g polypeptides, encoding nucleic acids and methods of use
WO2002005835A2 (en) 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
PL1618130T3 (pl) 2003-04-11 2013-08-30 Survac Aps Szczepionka terapeutyczna przeciw nowotworom

Also Published As

Publication number Publication date
ATE424842T1 (de) 2009-03-15
WO2005049073A3 (en) 2006-01-05
CA2546794A1 (en) 2005-06-02
KR101216655B1 (ko) 2013-01-02
HK1101131A1 (en) 2007-10-12
DK1691824T3 (da) 2009-07-06
JP2011246496A (ja) 2011-12-08
PT1691824E (pt) 2009-05-28
ES2436429T3 (es) 2014-01-02
US7842294B2 (en) 2010-11-30
RU2367468C2 (ru) 2009-09-20
KR20060132622A (ko) 2006-12-21
MXPA06005738A (es) 2006-12-14
KR20130026527A (ko) 2013-03-13
EP2087904A1 (en) 2009-08-12
AU2004290866B2 (en) 2010-09-02
EP1691824A2 (en) 2006-08-23
DE602004019965D1 (de) 2009-04-23
KR101284237B1 (ko) 2013-07-09
CN1921878B (zh) 2012-04-25
JP4926714B2 (ja) 2012-05-09
RU2006121466A (ru) 2007-12-27
EP1691824B1 (en) 2009-03-11
US20080050396A1 (en) 2008-02-28
CN1921878A (zh) 2007-02-28
ZA200604866B (en) 2008-05-28
EP2087904B1 (en) 2013-08-28
PL1691824T3 (pl) 2009-08-31
JP5502823B2 (ja) 2014-05-28
CA2546794C (en) 2013-09-17
ES2323588T3 (es) 2009-07-21
WO2005049073A2 (en) 2005-06-02
AU2004290866A1 (en) 2005-06-02
PL2087904T3 (pl) 2014-01-31
JP2007511547A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
DK2087904T3 (da) Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
AU2003270643A8 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
CY1114953T1 (el) Αντι-βητα-αμυλοειδους αντισωμα και χρησεις αυτου
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
IL164643A (en) Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE348632T1 (de) Prion protein peptide und deren verwendung
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
JP2008543961A5 (da)
ATE412671T1 (de) Modifizierter faktor viii
ATE460176T1 (de) Mikrosomvakzin
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
EA201070681A1 (ru) Пептиды fviii и их применение для индукции толерантности у больных гемофилией
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
ATE546462T1 (de) Peptide und derivate vom apl-typ von hsp60 und pharmazeutische zusammensetzungen
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
DK1474443T3 (da) Tolerogene peptider fra myelin-basisk-protein